Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Reviews Steaming Ahead, But Are Storm Clouds On The Horizon?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's generic office director notes a jump in year-end submissions – and a jump in refuse-to-receive actions.

You may also be interested in...



US FDA Outlines Internal ANDA Refuse-To-Receive Policy

Manual of Policies and Procedures document should provide more help to sponsors on what items must be in an ANDA for it to be reviewed.

US FDA Outlines Internal ANDA Refuse-To-Receive Policy

Manual of Policies and Procedures document should provide more help to sponsors on what items must be in an ANDA for it to be reviewed.

ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System

As more generic applications arrive, Office of Generic Drugs staff may have a tougher time reaching review goals.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS079144

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel